Abstract
The purpose of this study was to examine the production of IL-1β, IL-6 and TNF-α by peripheral blood mononuclear cells in patients with renal cell carcinoma treated with recombinant interleukin 2 (rIL-2). Peripheral blood mononuclear cells (PBMC) were purified from blood samples obtained six times during therapy and the production of IL-1β, IL-6 and TNF-α were determined after 18 h culture of the PBMC in culture medium or in medium containing 10 μg lipopolysaccharide (LPS)/ml, 10 ng LPS/ml or 1000 units rIL-2/ml. In vivo therapy with rIL-2 resulted in substantial changes in the production of the three cytokines. Only the production of TNF-α following in vitro stimulation with rIL-2 was related to the clinical response, being significantly lower in responding patients than in non-responders ( P < 0.05). These findings suggest that the rIL-2-induced TNF-α production of PBMC in vitro is lower in renal cancer patients that respond to rIL-2 therapy than in non-responding patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
